In a recent Baker Institute Blog post, Rice University junior and Baker Institute editorial intern Anna Schroeder writes about Paula Deen"s recent announcement that she has Type 2 diabetes diagnosis and her pursuant pharmaceutical endorsement. Schroeder asserts that Deen"s greatest fumble in handling the situation was simply touting the effectiveness of a pill instead of acknowledging the role that lifestyle choices play in Type 2 diabetes.
"Paula Deen had the perfect platform to address the American public, a population with a clear obesity epidemic and related diabetes outbreak, and comment on the importance of lifestyle choices. Instead, she ... shifted the discussion to the diabetes drug website she is promoting as a paid spokesperson."
May 19 2022 | Center for the Middle East
May 19 2022 | Center for Energy Studies